HC Wainwright & Co. Reiterates Buy on Onconova Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Onconova Therapeutics (NASDAQ:ONTX) and maintains an $11 price target.
June 14, 2023 | 4:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Onconova Therapeutics and maintains an $11 price target.
The Buy rating and maintained $11 price target by HC Wainwright & Co. analyst Joseph Pantginis indicates a positive outlook for Onconova Therapeutics. This reaffirmation of the Buy rating could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100